$865 million! AbbVie obtained a global interest in innovative therapies in the research system of lupus.

On June 18, Alpine Immune Sciences, Inc., a technology company focused on developing innovative treatments for cancer and autoimmune inflammatory diseases, announced that it had reached an agreement with AbbVie on a global license for alPN-101Alpine's shares jumped 211 percent in pre-market trading after the newsunder the terms of the agreement, Alpine will receive an advance payment of $60 million and will be eligible for payments totalling up to $805 million based on exercise options, research and development, regulation and commercial milestonesIn addition, Alpine receives tiered royalties from the net sales of alPN-101Through this transaction, AbbVie will receive the alPN-101's global exclusive licensing optionDuring the option period, Alpine will conduct a Phase 2 clinical study of systemic lupus, after which AbbVie will be responsible for future clinical development, manufacturing and commercialization of ALPN-101ALPN-101 is a pioneering CD28/ICOS dual irritant, currently in the clinical phase 2 research and development phaseCD28 and ICOS are costimulant synopsis that play a key role in a variety of autoimmune and inflammatory diseasesALPN-101 is an effective inhibitor of the CD28/ICOS pathway and has been shown to be superior to a single blocking pathway in a number of preclinical disease modelsGood safety, tolerance, pharmacokinetics and pharmacodynamics were shown in adult healthy volunteersOn The 8th of this month, Alpine updated the data of alPN-101's Phase 1 clinical trial in healthy volunteers at the European Union meeting against rheumatismThe trial included 96 healthy adults, randomly grouped, received a dose of ALPN-101 or placebo at a dose of 1 mg/kg-10 mg/kg, and administered the drug through one or more intravenous or subcutaneous injectionsThe results showed that at all dose levels, the drug showed no serious side effects, no obvious immunogenicity or cytokine release in the clinic, and showed an ideal dose-dependent doseDr Mitchell HGold, Chief Executive Officer and Executive Chairman of Alpine, said, "We are very pleased to have partnered with AbbVie on the development of the ALPN-101AbbVie is an ideal partner for ALPN-101, with the expertise, research and development support, and global resources needed to maximize the potential of ALPN-101 in patients with autoimmune diseasesDr Tom Hudson, Senior Vice President and CEO of AbbVie, said, "As a new generation of therapies for systemic lupus and other autoimmune diseases, the dual-role mechanism of ALPN-101 has the potential to be significantReferences: 1, Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101 2, AbbVie and Alpine Immune Ink $865 Million Deal to License Drug for Lupus and Other Other Diseases.